阻断多巴胺D3受体改善海马突触功能,并拯救与年龄相关的认知表型
Maria Rosaria Tropea1, Marcello Melone2,3, Domenica Donatella Li Puma4,5
1Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Aging cell
|September 5, 2024
概括
阻断多巴胺D3受体 (D3Rs) 增强海马突触功能和成年小鼠的记忆形成. 这种阻塞还可以通过改善老年小鼠的突触可塑性和记忆来逆转与年龄相关的认知衰退.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 认知科学 认知科学
背景情况:
- 已知多巴胺D3受体 (D3Rs) 在像海马体这样的大脑区域调节神经元活动.
- 以前的研究表明,阻断D3Rs可能会改善认知功能.
- D3Rs在海马突触功能和记忆中的特定作用,特别是在衰老中,需要进一步研究.
研究的目的:
- 研究D3Rs在海马突触功能和健康和老年大脑的记忆中的作用.
- 确定D3R阻断或遗传删除对突触可塑性和记忆形成的影响.
- 探索针对D3Rs针对与年龄相关的认知衰退的治疗潜力.
主要方法:
- 使用了成年野生型 (WT) 鼠和D3受体淘汰 (KO) 鼠.
- 使用的药理阻断D3Rs.
- 评估了长期强化 (LTP),基础突触传输 (BST) 和记忆形成.
- 通过电子显微镜分析了后突触蛋白表达 (PSD-95,p-GluA1,p-CREB) 和突触结构.
主要成果:
- D3R阻塞或KO通过cAMP/PKA通路将弱LTP转化为强LTP (LTP2),使成年小鼠能够形成长期记忆.
- 后突触机制,包括增强的BST,AMPAR电流,mEPSC振幅和关键蛋白质表达,介导D3R效应.
- 在老年小鼠中,D3R阻断逆转了LTP,BST,记忆和突触后蛋白质表达的损伤,老年D3-KO小鼠没有出现缺陷.
结论:
- 多巴胺D3受体在海马突触功能和记忆中发挥着基本作用.
- D3R活动对于维持认知功能至关重要,与年龄相关的D3Rs减少会影响突触可塑性和记忆力.
- 准D3R是一种潜在的治疗策略,可以抵消与年龄相关的海马体认知衰退.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
110
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454


